Herbert Hurwitz

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

H. Hurwitz, C. Sweeney, E. Chiorean, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.